Evidence map›Paper›PMID 42339725›Full record

ArticleZoological research2026

AI-aided design of multi-epitope peptide vaccine elicits cellular and humoral immunity to broad Omicron subvariants.

Kai Zhang, Gangao Wang, Tingting Liu, Min Li, Longfei Ding, Yanqi Zhao, Jianqing Xu, Honglin Li, Jianhua Sun, Xinxin Zhang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zoological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kai ZhangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.
Gangao WangInnovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai 200062, China.
Tingting LiuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Min LiState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing 100071, China.
Longfei DingShanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Fudan University, Shanghai 201508, China.
Yanqi ZhaoShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Jianqing XuShanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Fudan University, Shanghai 201508, China.
Honglin LiInnovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai 200062, China.
Jianhua SunState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Xinxin ZhangShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
Jing ChenSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.
Guangyu ZhaoState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing 100071, China. E-mail: zhaoguangyu@bmi.ac.cn.
Xingchao GengInstitute for Biological Product Control, National Institutes for Food and Drug Control, Beijing 100176, China. E-mail: gengxch@nifdc.org.cn.
Yiru LongState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. E-mail: s18-longyiru@simm.ac.cn.
Likun GongSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptide vaccines offer a flexible, rapidly updatable platform for responding to SARS-CoV-2 antigenic drift. However, many candidates target a single epitope class, predominantly CD4

Indexed as

COVID-19COVID-19 VaccinesImmunity, CellularImmunity, HumoralSARS-CoV-2AnimalsComputer-Aided DesignEpitopesEpitopes, T-LymphocyteHumansImmunoinformaticsMiceProtein Subunit VaccinesSpike Glycoprotein, CoronavirusVaccines, SubunitCOVID-19 VaccinesEpitopesEpitopes, T-LymphocyteProtein Subunit VaccinesSpike Glycoprotein, CoronavirusVaccines, SubunitAI-aided designPeptide vaccineSARS-CoV-2T- and B-cell epitopes

Identifiers

PMID42339725
PMCPMC13647155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.